COCHLEAR LTD/ AU000000COH5 /
4/25/2025 8:54:38 AM | Chg. -0.5600 | Volume | Bid11:11:21 AM | Ask9:04:50 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
147.7200EUR | -0.38% | 0 Turnover: 0.0000 |
147.0800Bid Size: 300 | 151.5800Ask Size: 300 | 9.79 bill.EUR | - | - |
GlobeNewswire
3/10
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Busi...
GlobeNewswire
2/24
Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children ...
GlobeNewswire
8/13/2024
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/12/2024
Envoy Medical Reports Second Quarter 2024 Results and Provides Business Update
GlobeNewswire
8/5/2024
Kronos Advanced Technologies Inc. and Yasheng Group Announce Strategic Collaboration to Develop Revo...
GlobeNewswire
7/31/2024
Bipartisan Senate Bill Seeks to Clarify that Implanted Active Middle Ear Hearing Devices are Prosthe...
GlobeNewswire
7/16/2024
Genetic Technologies Announces Appointment of Chief Financial Officer & Company Secretary
GlobeNewswire
6/20/2024
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Ver...
GlobeNewswire
6/11/2024
Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Director...
GlobeNewswire
6/5/2024
Newly Published Peer-Reviewed Article Highlights Advances in Fully Implanted Cochlear Implant Techno...
GlobeNewswire
5/14/2024
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/8/2024
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire
4/3/2024
Envoy Medical to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
GlobeNewswire
3/21/2024
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Busi...
GlobeNewswire
3/20/2024
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneou...